Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.17%
#3 OpenEden OpenEden +11.49%
#4 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.67%
#5 Mantle Staked Ether Mantle Staked Ether +8.27%
#6 Palladium Network Palladium Network +7.82%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.66%
#8 Prom Prom +6.59%
#9 Zest Protocol Zest Protocol +6.19%
#10 EfficientFrontier EfficientFrontier +4.43%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Synairgen plc Synairgen plc

Synairgen plc

SNG
Classement en actions #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Prix de l'action
$0.01292666
Dernière synchronisation: 2025-04-08
Capitalisation boursière
$157.54K
Changement (1 jour)
6.84%
Changement (1 an)
0.00%
Pays
GB
Échange Synairgen plc (SNG)

Catégorie

Healthcare
Bénéfices pour Synairgen plc (SNG)
Bénéfices en Jun 2024 TTM : $-4.64M
Selon les derniers rapports financiers de Synairgen plc, les bénéfices actuels de l'entreprise sont de $-4.64M. En 2022, l'entreprise a réalisé un bénéfice de $-24.31M, une augmentation par rapport à celui de 2021 qui était de $-78.22M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Synairgen plc de 2004 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -113,800.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -42,146.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -64,888.45%
BE